The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

2024.01.19
Dr. Wenshi Wang is the Principal Investigator of the hepatitis virus research group, Xuzhou Medical University, China. He obtained his Ph.D. from Erasmus University Rotterdam, the Netherlands, and completed post-doc research training at Heidelberg University, Germany in the field of hepatitis viruses. He has contributed more than 50 peer-reviewed publications, with 20 first or corresponding authorships in peer-reviewed academic journals such as Journal of Hepatology, Gastroenterology, Hepatology, Trends in Microbiology, Science Signaling, and JHEP Reports. He received the Kiem Award from the Royal Netherlands Society for Microbiology (2017), the EASL Sheila Sherlock Fellowship (2018) from the European Association for the Study of Liver, and the 1st Prize NVGE Gastro-intestinal Research Award from the Netherlands Society of Gastroenterology (2019). Currently, his group is committed to basic and translational research on hepatitis viruses with the following research focus:(1) Understanding the molecular and cellular mechanisms that orchestrate the hepatitis virus replication cycles; (2) Studying the host-virus interaction by employing molecular and cellular biology techniques; (3) Developing antiviral candidates and understanding their mode of action; (4) Studying the host metabolic changes and the possible consequences on virus infection.
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

2024.01.18
According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally advanced/metastatic solid tumor patients with KRAS G12C mutation. It involves patients with an ECOG PS of 0-1, measurable disease according to RECIST v1.1 standards. The main objectives are to determine the recommended phase II dose (RP2D) of LY3537982, its safety, pharmacokinetics (PK), and antitumor activity. Patients were divided into four dosage groups: 50 mg, 100 mg, 150 mg, and 200 mg taken twice daily. Dose expansion cohorts included combination treatments of LY3537982 with pembrolizumab (for NSCLC) and cetuximab (for CRC).
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

2024.01.18
The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year's AACR conference, three clinical trials were reported in the lymphoma field, including anti-CD19 immunotherapy Tafasitamab, CD19/CD20 CAR naive/memory T cells, and bispecific quadrivalent antibody (innate cell engager) AFM13.
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

2024.01.18
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract

KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract

2024.01.18
According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this approach demonstrated consistent survival benefits across geographical regions and PD-L1 expression subgroups. The KEYNOTE-966 study results were concurrently published in "The Lancet."